Axol Bioscience is meeting Metrion Biosciences for a whole day stem cell event, on May 23, 2018. Don't miss the opportunity to see some excellent scientific presentations.
Our team has spent the first few months of 2018 working hard to introduce an exciting new range of products to the Axol catalog. As well as the Primary and iPS derived human cells Axol is know for; we can now offer researchers the convenience of sourcing antibodies, kits and other reagents in one place.
We are attending the ELRIG Research & Innovation Meeting 2018 in Cambridge, UK, from 17-18 April 2018. We will be available throughout the conference at booth 7, during our Spotlight Sessions about Microglia and Neural Cells as well as our Poster. Join us!
We are attending the SOT Annual Meeting 2018 in Texas, from 11-15 March 2018. We will be available throughout the conference at booth 760 as well as in our workshop, March 12. Join us!
Since a funding injection by our investors in 2017, we have been working hard to double our manufacturing capacity and bring some exciting new products to market. Cells will always be the (beating) heart of what we do at Axol, but we know that until now our customers have had to look elsewhere for antibodies, kits and other reagents.
Are you popping over to Cambridge for the 6th Cambridge International Stem Cell Symposium? Why not to join our networking event the night before?
Are you attending SLAS 2018? Meet with our product experts and discuss about Axol's latest innovations and technologies. We will be at booth #450, or you can find us at our spotlight session or our workshop.
Are you attending SfN 2017?. Check out Axol's latest product innovations on our booth as well as in our workshop.
Specialist stem cell biotech Axol Bioscience enhances its future scientific and commercial endeavours
Private equity firm Calculus Capital, a leading EIS and VCT investor, has further expanded its life science portfolio, by investing £2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells.
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Axol Bioscience
We hereby announce that ID Pharma Co., Ltd., a wholly owned subsidiary of our company (hereinafter "ID Pharma") has entered into a licensing agreement with Axol Bioscience to enable them to produce iPS cells using the CytoTune®-iPS technology ( 1 ) owned by ID Pharma, and to supply and sell differentiated cells derived from these iPS cells as research products.
Cambridge, UK, 26 July 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells, and Metrion Biosciences, a specialist ion channel drug discovery business, have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias. This is in accordance with the FDA’s Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to revise cardiac safety testing regulations.
Under the terms of the agreement, Metrion will use Axol’s human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing and translational phenotypic assays. Combining Metrion's contract research services and assay development capabilities with Axol’s human iPSC-derived cells and culture reagents will provide a source of well-validated, CiPA-compliant stem cell-derived assays and services for use in predictive toxicology as well as drug discovery screening.
MESO-BRAIN Initiative Receives €3.3 Million to Replicate Brain’s Neural Networks Through 3D Nanoprinting
BIRMINGHAM, CAMBRIDGE, HUDDERSFIELD (UK), HANNOVER (Germany), BARCELONA (Spain), 9 June 2016: The MESO-BRAIN consortium has received a prestigious award of €3.3 million in funding from the European Commission as part of its Future and Emerging Technology (FET) scheme. The project aims to develop three-dimensional (3D) human neural networks with specific biological architecture, and the inherent ability to interrogate the network’s brain-like activity both electrophysiologically and optically. It is expected that the MESO-BRAIN will facilitate a better understanding of human disease progression, neuronal growth and enable the development of large-scale human cell-based assays to test the modulatory effects of pharmacological and toxicological compounds on neural network activity. The use of more physiologically relevant human models will increase drug screening efficiency and reduce the need for animal testing.
Cambridge, UK, 1 June 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three exciting products at International Society for Stem Cell Research (ISSCR) 2016 taking place in San Francisco, CA from 22 - 25 June. This includes: Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery plc. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes.
Cambridge, UK, 12 May 2016: Axol Bioscience, a biotechnology company specialising in the supply of human iPSC-derived cells has expanded its range of neuroscience research tools to include an iPSC-Derived Astrocyte Progenitor Kit and iPSC-Derived Mature Astrocyte Kit . Axol iPSC-Derived Astrocyte Kits include cryopreserved cells, optimised media and supplements. The new kits offer researchers a complete culture system that is easy to use and promotes long-term cell viability for use in disease modelling and drug discovery applications.
Cambridge, UK, 28 April 2016: Axol Bioscience, a biotechnology company specialising in the supply of primary and stem cell-derived human cells for use in disease modelling and drug discovery, announces the launch of its Custom Cell and Tissue Sourcing service. The new service will be of use to all researchers working in these areas who require access to primary human cells and tissues. These can be difficult to obtain, especially when studying rare diseases or specific donor criteria are required. Axol aims to provide cells and tissues that meet specific research requirements to enable the development of highly relevant cellular models that better reflect the biology of the tissue or disease.
Cambridge, UK, 19 April 2016: Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease-relevant cell based assay systems for drug discovery and disease modelling, today announced that Steve Finkbeiner, MD, PhD has joined its Scientific Advisory Board. Dr Finkbeiner is a leading neuroscientist who will guide Axol in expanding its range of induced pluripotent stem cell (iPSC)-derived neural cells and culture systems to ensure that the company continues to bring innovative products to market. Dr Finkbeiner is renowned for his research in neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and Huntington’s, Parkinson’s and Alzheimer’s diseases. He is perhaps best known for his invention of a robotic imaging device that has helped to elucidate the mechanisms behind learning, memory formation and neurodegeneration.
Cambridge, UK, 22 February 2016: Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today announced Paul Andrews as their Scientific Advisory Board Member. Dr Andrews is an expert in the industrial application of stem cells in phenotypic screening, having previously used this platform to identify agents that steer cell fate. He will aid Axol in ensuring its commercially available human primary and induced pluripotent stem cell (iPSC)-derived cells continue to enable the development of pathophysiologically-relevant systems for industrial and academic research.
Cambridge, UK, 28 January 2016: Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today appointed Prof Chas Bountra to their Scientific Advisory Board (SAB). Chas Bountra is recognised for his open access approach to drug discovery and has made several noteworthy contributions to the field. A pioneer in the identification and validation of numerous drug targets, he has formed a number of successful collaborations between the public and private sectors to implement more efficient strategies for drug discovery. Prof Bountra will aid Axol in building stronger links within this community and identify key areas where its primary and iPSC-derived human cells could help recognise relevant drug targets sooner and accelerate progress into development.
Cambridge, UK, 20 January 2016: Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB). Dr Rees will be attending the fifth annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA from 23-27 January 2016, where Axol will showcase the newest addition to its growing range of primary and induced pluripotent stem cell (iPSC)-derived cells for drug discovery through several poster presentations and an exhibitor tutorial.
Cambridge, UK, 12 January 2016: Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced Prof Xianmin Zeng, PhD as Chief Scientific Officer (CSO). Prof Zeng is an accomplished biologist with over 15 years of academic expertise in the development of stem cell technologies and its applications. A biotech entrepreneur with an extensive list of peer-reviewed publications, she is a well-established and internationally-recognised leader in the creation of disease models for drug discovery.